Inactivated Pneumococcal Type 15B Antigen_天津卡梅德科技发展有限公司

>>

>>

>>

>

Inactivated Pneumococcal Type 15B Antigen

Inactivated Pneumococcal Type 15B Antigen

产品编号

BAG1121

别名

灭活15B型肺炎球菌抗原,灭活肺炎球菌抗原, 肺炎球菌, Inactivated Pneumococcal Type 15B, Pneumococcal

规格

250ul
1ml

DATASHEET MSDS

立即询价加入询价列表大包装定制

产品介绍

Catalog Number	BAG1121
Alias	灭活15B型肺炎球菌抗原,灭活肺炎球菌抗原, 肺炎球菌, Inactivated Pneumococcal Type 15B, Pneumococcal
Size	250ul, 1ml
Molecular Name	Pneumococcal
Expression System	Pneumococcal
Species	Bacteria
Purity	>95%
Purification	IEC & HPLC
Storage Condition	Store the lyophilized powder at 4℃ for 6 months. It is recommended to aliquote to ~10ul per vial and store at -20℃ for long term storage. Avoid repeated freezing and thawing cycles.
Formulation	Powder or 0.1M PBS, PH 7.0
Background	In most cases, once pneumococcal pneumonia has been identified, doctors will prescribe antibiotics. These antibiotic usually help alleviate and eliminate symptoms between 12 and 36 hours after being taken. Despite most antibiotics' effectiveness in treating the disease, sometimes the bacteria can resist the antibiotics, causing symptoms to worsen. Additionally, age and health of the infected patient can contribute to the effectiveness of the antibiotics.
Application	Immunogen, WB, ELISA

FAQ

为什么选择CRM197作为载体蛋白，而不是其他蛋白（如破伤风类毒素TT或白喉类毒素DT）？

CRM197相较于其他传统载体蛋白有几个显著优势：安全性高：作为天然白喉毒素的无毒突变体，其安全性记录极佳，大规模使用中不良反应率低。免疫原性强：能非常有效地刺激辅助T细胞，产生强大的免疫增强效果。无预存免疫干扰：在婴幼儿中，对白喉毒素/CRM197的预存抗体水平通常很低。相比之下，使用TT或DT作为载体时，母亲传给的抗体或婴儿常规接种的百白破疫苗可能产生预存抗体，理论上可能干扰新结合疫苗的免疫效果。CRM197在一定程度上避免了这种潜在干扰。工艺成熟：其重组生产技术成熟稳定，易于实现大规模、高纯度的生产。

推荐产品

400-621-6806
18630936064（微信同号）
周一至周五 8:30-18:00
0